Gelsolin and progression of aortic arch calcification in chronic hemodialysis patients

International Journal of Medical Sciences

Volumn 13, Issue 2, 2016, Pages 92-98

  Chiou, Terry Ting Yu ^a   Liao, Shang Chih ^a   Kao, Yu Yin ^a   Lee, Wen Chin ^a   Lee, Yueh Ting ^a   Ng, Hwee Yeong ^a   Lee, Po Shun ^b   Lee, Chien Te ^a  

^a CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Aortic arch calcification; Gelsolin; Hemodialysis

Indexed keywords

ALBUMIN; C REACTIVE PROTEIN; CALCIUM; CHOLESTEROL; GELSOLIN; INTERLEUKIN 6; PARATHYROID HORMONE; PHOSPHATE; TUMOR NECROSIS FACTOR ALPHA; BIOLOGICAL MARKER;

AGE DISTRIBUTION; ALBUMIN BLOOD LEVEL; ARTERY CALCIFICATION; ARTICLE; CALCIUM BLOOD LEVEL; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DISEASE COURSE; DISEASE SEVERITY; HEMODIALYSIS; HEMODIALYSIS PATIENT; HIGH RISK PATIENT; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; PARATHYROID HORMONE BLOOD LEVEL; PHOSPHATE BLOOD LEVEL; PREVALENCE; PROTEIN BLOOD LEVEL; RISK ASSESSMENT; RISK FACTOR; VASCULAR DISEASE; WAIST CIRCUMFERENCE; ADULT; ADVERSE EFFECTS; AGED; BLOOD; DIAGNOSTIC IMAGING; MIDDLE AGED; PATHOPHYSIOLOGY; THORACIC AORTA; THORAX RADIOGRAPHY; VASCULAR CALCIFICATION;

ADULT; AGED; AORTA, THORACIC; BIOMARKERS; GELSOLIN; HUMANS; MIDDLE AGED; RADIOGRAPHY, THORACIC; RENAL DIALYSIS; VASCULAR CALCIFICATION;

EID: 84956930035     PISSN: 14491907     EISSN: None     Source Type: Journal    
DOI: 10.7150/ijms.13785     Document Type: Article

References (40)

1. 1 Collins AJ, Li S, Ma JZ, Herzog C. Cardiovascular disease in end-stage renal disease patients. Am J Kidney Dis. 2001; 38: S26-29.
2. 2 McIntyre CW. The functional cardiovascular consequences of vascular calcification. Semin Dial. 2007; 20: 122-128.
3. 3 Cannata-Andia JB, Rodriguez-Garcia M, Carrillo-Lopez N, Naves-Diaz M, Diaz-Lopez B. Vascular calcifications: Pathogenesis, management, and impact on clinical outcomes. J Am Soc Nephrol. 2006; 17: S267-273.
4. 4 Rennenberg RJ, Kessels AG, Schurgers LJ, van Engelshoven JM, de Leeuw PW, Kroon AA. Vascular calcifications as a marker of increased cardiovascular risk: A meta-analysis. Vasc Health Risk Manag. 2009; 5: 185-197.
5. 5 Lee CT, Huang CC, Hsu CY, Chiou TT, Ng HY, Wu CH, Kuo WH, Lee YT. Calcification of the aortic arch predicts cardiovascular and all-cause mortality in chronic hemodialysis patients. Cardiorenal Med. 2014; 4: 34-42.
6. 6 Goldsmith DJ, Covic A, Sambrook PA, Ackrill P. Vascular calcification in long-term haemodialysis patients in a single unit: A retrospective analysis. Nephron. 1997; 77: 37-43.
7. 7 Ammirati AL, Dalboni MA, Cendoroglo M, Draibe SA, Santos RD, Miname M, Canziani ME. The progression and impact of vascular calcification in peritoneal dialysis patients. Perit Dial Int. 2007; 27: 340-346.
8. 8 Kim HG, Song SW, Kim TY, Kim YO. Risk factors for progression of aortic arch calcification in patients on maintenance hemodialysis and peritoneal dialysis. Hemodial Int. 2011; 15: 460-467.
9. 9 Ogawa T, Ishida H, Akamatsu M, Matsuda N, Fujiu A, Ito K, Ando Y, Nitta K. Relation of oral 1alpha-hydroxy vitamin d3 to the progression of aortic arch calcification in hemodialysis patients. Heart Vessels. 2010; 25: 1-6.
10. 10 Tamei N, Ogawa T, Ishida H, Ando Y, Nitta K. Serum fibroblast growth factor-23 levels and progression of aortic arch calcification in non-diabetic patients on chronic hemodialysis. J Atheroscler Thromb. 2011; 18: 217-223.
11. 11 Shroff R, Long DA, Shanahan C. Mechanistic insights into vascular calcification in CKD. J Am Soc Nephrol. 2013; 24: 179-189.
12. 12 Sigrist MK, Taal MW, Bungay P, McIntyre CW. Progressive vascular calcification over 2 years is associated with arterial stiffening and increased mortality in patients with stages 4 and 5 chronic kidney disease. Clin J Am Soc Nephrol. 2007; 2: 1241-1248.
13. 13 Noordzij M, Cranenburg EM, Engelsman LF, Hermans MM, Boeschoten EW, Brandenburg VM, Bos WJ, Kooman JP, Dekker FW, Ketteler M, Schurgers LJ, Krediet RT, Korevaar JC, Group NS. Progression of aortic calcification is associated with disorders of mineral metabolism and mortality in chronic dialysis patients. Nephrol Dial Transplant. 2011; 26: 1662-1669.
14. 14 Iribarren C, Sidney S, Sternfeld B, Browner WS. Calcification of the aortic arch: Risk factors and association with coronary heart disease, stroke, and peripheral vascular disease. JAMA. 2000; 283: 2810-2815.
15. 15 Blacher J, Guerin AP, Pannier B, Marchais SJ, London GM. Arterial calcifications, arterial stiffness, and cardiovascular risk in end-stage renal disease. Hypertension. 2001; 38: 938-942.
16. 16 Chen NX, Moe SM: Vascular calcification: Pathophysiology and risk factors. Curr Hypertens Rep. 2012; 14: 228-237.
17. 17 Lee CT, Chua S, Hsu CY, Tsai YC, Ng HY, Kuo CC, Wu CH, Chen TC, Chiu TT, Lee YT. Biomarkers associated with vascular and valvular calcification in chronic hemodialysis patients. Dis Markers 2013; 34: 229-235.
18. 18 Bucki R, Levental I, Kulakowska A, Janmey PA. Plasma gelsolin: Function, prognostic value, and potential therapeutic use. Curr Protein Pept Sci. 2008; 9: 541-551.
19. 19 Lee WM, Galbraith RM. The extracellular actin-scavenger system and actin toxicity. N Engl J Med. 1992; 326: 1335-1341.
20. 20 Suhler E, Lin W, Yin HL, Lee WM. Decreased plasma gelsolin concentrations in acute liver failure, myocardial infarction, septic shock, and myonecrosis. Crit Care Med. 1997; 25: 594-598.
21. 21 Osborn TM, Dahlgren C, Hartwig JH, Stossel TP. Modifications of cellular responses to lysophosphatidic acid and platelet-activating factor by plasma gelsolin. Am J Physiol Cell Physiol. 2007; 292: C1323-1330.
22. 22 Bucki R, Kulakowska A, Byfield FJ, Zendzian-Piotrowska M, Baranowski M, Marzec M, Winer JP, Ciccarelli NJ, Gorski J, Drozdowski W, Bittman R, Janmey PA. Plasma gelsolin modulates cellular response to sphingosine 1-phosphate. Am J Physiol Cell Physiol. 2010; 299: C1516-1523.
23. 23 Chellaiah M, Kizer N, Silva M, Alvarez U, Kwiatkowski D, Hruska KA. Gelsolin deficiency blocks podosome assembly and produces increased bone mass and strength. J Cell Biol. 2000; 148: 665-678.
24. 24 Lee PS, Sampath K, Karumanchi SA, Tamez H, Bhan I, Isakova T, Gutierrez OM, Wolf M, Chang Y, Stossel TP, Thadhani R. Plasma gelsolin and circulating actin correlate with hemodialysis mortality. J Am Soc Nephrol. 2009; 20: 1140-1148.
25. 25 Chiu TT, Liao SC, Lee WC, Lee PS, Ng HY, Chien YS, Lee CT. Gelsolin and adipokines are associated with protein-energy wasting in hemodialysis patients. Artif Organs. 2015; 39: 150-155.
26. 26 Gotch FA, Sargent JA. A mechanistic analysis of the national cooperative dialysis study (NCDS). Kidney Int. 1985; 28: 526-534.
27. 27 Symeonidis G, Papanas N, Giannakis I, Mavridis G, Lakasas G, Kyriakidis G, Artopoulos I. Gravity of aortic arch calcification as evaluated in adult greek patients. Int Angiol. 2002; 21: 233-236.
28. 28 Chellaiah M, Hruska K. Osteopontin stimulates gelsolin-associated phosphoinositide levels and phosphatidylinositol triphosphate-hydroxyl kinase. Mol Biol Cell. 1996; 7: 743-753.
29. 29 Persy V, D'Haese P. Vascular calcification and bone disease: The calcification paradox. Trends Mol Med. 2009; 15: 405-416.
30. 30 Yang Z, Chiou TT, Stossel TP, Kobzik L. Plasma gelsolin improves lung host defense against pneumonia by enhancing macrophage nos3 function. Am J Physiol Lung Cell Mol Physiol. 2015; 309: L11-16.
31. 31 Lee PS, Waxman AB, Cotich KL, Chung SW, Perrella MA, Stossel TP. Plasma gelsolin is a marker and therapeutic agent in animal sepsis. Crit Care Med. 2007; 35: 849-855.
32. 32 Nishikawa M, Kurano M, Ikeda H, Aoki J, Yatomi Y. Lysophosphatidylserine has bilateral effects on macrophages in the pathogenesis of atherosclerosis. J Atheroscler Thromb. 2015; 22: 518-526.
33. 33 de la Cuesta F, Zubiri I, Maroto AS, Posada M, Padial LR, Vivanco F, Alvarez-Llamas G, Barderas MG. Deregulation of smooth muscle cell cytoskeleton within the human atherosclerotic coronary media layer. J Proteomics. 2013; 82: 155-165.
34. 34 de la Cuesta F, Barderas MG, Calvo E, Zubiri I, Maroto AS, Darde VM, Martin-Rojas T, Gil-Dones F, Posada-Ayala M, Tejerina T, Lopez JA, Vivanco F, Alvarez-Llamas G. Secretome analysis of atherosclerotic and non-atherosclerotic arteries reveals dynamic extracellular remodeling during pathogenesis. J Proteomics. 2012; 75: 2960-2971.
35. 35 Genre F, Lopez-Mejias R, Miranda-Filloy JA, Ubilla B, Carnero-Lopez B, Gomez-Acebo I, Blanco R, Ochoa R, Rueda-Gotor J, Gonzalez-Juanatey C, Llorca J, Gonzalez-Gay MA. Gelsolin levels are decreased in ankylosing spondylitis patients undergoing anti-tnf-alpha therapy. Clin Exp Rheumatol. 2014; 32: 218-224.
36. 36 Han C, Zhang L, Zhu X, Tang J, Jin X. Plasma gelsolin levels are decreased and correlate with fibrosis in IgA nephropathy. Exp Biol Med. 2013; 238: 1318-1327.
37. 37 Forsman H, Onnheim K, Andreasson E, Christenson K, Karlsson A, Bylund J, Dahlgren C. Reactivation of desensitized formyl peptide receptors by platelet activating factor: A novel receptor cross talk mechanism regulating neutrophil superoxide anion production. PLoS One. 2013; 8: e60169.
38. 38 Chan W, Lau L, Kwok K, Law W, Ho JCM, Chu K, Poon RTP. A randomized, double-blind, placebo-controlled, ascending-dose trial of the pharmacokinetics and safety of intravenous infusion of recombinant human plasma gelsolin in acutely ill patients with decreased plasma gelsolin levels. American Thoracic Society. 2011; 183: A5601.
39. 39 Aoqui C, Cuppari L, Kamimura MA, Canziani ME. Increased visceral adiposity is associated with coronary artery calcification in male patients with chronic kidney disease. Eur J Clin Nutr. 2013; 67: 610-614.
40. 40 Kevin Li-Chun H, Schob S, Zeller MW, Pulli B, Ali M, Wang C, Chiou TT, Tsang YM, Lee PS, Stossel TP, Chen JW. Gelsolin decreases actin toxicity and inflammation in murine multiple sclerosis. J Neuroimmunol. 2015; 287: 36-42.